My goodness!!
I wonder if the FDA will demand much more onerous tox studies if this ruling holds up?
Will still be important to perform efficacy trials, but with Cormasine Phase II might be enough to generate enough interest to really get sales moving. Note though the ruling apparently only applies where there is no other treatment. So even a useless one if available would close the loophole. Not sure there aren't (useless)treatments available for RCC and Melanoma already which would defeat this advantage for Cormasine?
- Forums
- ASX - By Stock
- SBP
- re: fda approval
SBP
solbec pharmaceuticals limited
re: fda approval
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)